Report of the task force on designing clinical trials in early (predementia) AD

BACKGROUND: A large number of promising candidate disease-modifying treatments for Alzheimer disease (AD) continue to advance into phase II and phase III testing. However, most completed trials have failed to demonstrate efficacy, and there is growing concern that methodologic difficulties may contr...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Aisen, P.S., Andrieu, S., Sampaio, C., Carrillo, M., Khachaturian, Z.S., Dubois, B., Feldman, H.H., Petersen, R.C., Siemers, E., Doody, R.S., Hendrix, S.B., Grundman, M., Schneider, L.S., Schindler, R.J., Salmon, E., Potter, W.Z., Thomas, R.G., Salmon, D., Donohue, M., Bednar, M.M., Touchon, J., Vellas, B.
Médium: Artigo
Jazyk:Inglês
Vydáno: Lippincott Williams & Wilkins 2011
Témata:
Views and Reviews
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3034393/
https://ncbi.nlm.nih.gov/pubmed/21178097
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1212/WNL.0b013e318207b1b9
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky